N-(4-Methyl-3-nitro-phenyl)-3-morpholin-4-yl-5-trifluoromethyl-benzamide | 250682-10-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-Methyl-3-nitro-phenyl)-3-morpholin-4-yl-5-trifluoromethyl-benzamide
• CAS: 250682-10-1
• 化学式: C₁₉H₁₈F₃N₃O₄
• 分子量: 409.365
• InChiKey: WFURTDGESMUYFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.01
• 重原子数：
  29.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  84.71
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  N-(4-Methyl-3-nitro-phenyl)-3-morpholin-4-yl-5-trifluoromethyl-benzamide 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基乙酰胺 为溶剂， 生成 N-{4-Methyl-3-[4-(pyridin-2-ylmethoxy)-benzoylamino]-phenyl}-3-morpholin-4-yl-5-trifluoromethyl-benzamide
  参考文献：
  名称：

  A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis

  摘要：

  A novel p38 MAP kinase inhibitor structural class was discovered through selectivity screening. The rational analogue design, synthesis and structure-activity relationship of this series of bisamide inhibitors is reported. The inhibition in vitro of human p38alpha enzyme activity and lipopolysaccharide-induced tumour necrosis factor-alpha release is described for the series. The activity in vivo and pharmacokinetic properties are exemplified for the more potent analogues. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.006
• 作为产物：
  描述：

  3-吗啉-5-(三氟甲基)苯甲酸 在 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(4-Methyl-3-nitro-phenyl)-3-morpholin-4-yl-5-trifluoromethyl-benzamide
  参考文献：
  名称：

  A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis

  摘要：

  A novel p38 MAP kinase inhibitor structural class was discovered through selectivity screening. The rational analogue design, synthesis and structure-activity relationship of this series of bisamide inhibitors is reported. The inhibition in vitro of human p38alpha enzyme activity and lipopolysaccharide-induced tumour necrosis factor-alpha release is described for the series. The activity in vivo and pharmacokinetic properties are exemplified for the more potent analogues. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.006